Abstract
Many studies have demonstrated that 18-fluorine fluorodeoxyglucose positron emission tomography (FDG-PET) is useful for predicting the grade of malignancy of thymic epithelial tumors (TETs), and there is a close relationship between the maximum standardized uptake value (SUVmax) and tumor stage. However, more specific usage of FDG-PET for TETs has not been proposed, and the actual value of FDG-PET in routine clinical practice should be firmly clarified. In this review, following three cutoff values of SUVmax that may be helpful in determining treatment strategies in cases of anterior mediastinal masses, particularly presented as discrete and resectable lesions, are identified: (I) SUVmax of 7.5 as an indicator for pretreatment biopsy: differential diagnosis between TETs and mediastinal lymphoma (ML); (II) SUVmax of 4.2 as an indicator for a minimally invasive approach (MIA): differentiation of noninvasive TETs and invasive TETs; and (III) SUVmax of 5.9 as a reference value for the necessity of lymph node dissection (LND). There are still several challenges in using FDG-PET for routine clinical practice that need to be addressed, such as variations between instruments and institutions, leading to lower reproducibility. Harmonization methods should be applied to make clinical practice more uniform. Due to the rarity of these diseases, multi-institutional studies are warranted.